abs375.txt	most	ovarian	cancer	patients	respond	well	to	initial	platinum-based	chemotherapy	however		within	a	year	many	experience	disease	recurrence	with	aplatinum	resistant	phenotype	that	responds	poorly	second	line	chemotherapies	as	result	new	strategies	address	platinum	(proc)are	needed	herein	we	report	np	co-delivery	of	cisplatin	(cp)	andwortmannin	(wtmn)	dna	repair	inhibitor	synergistically	enhanceschemoradiotherapy	(crt)	and	reverses	cp	resistance	in	proc	encapsulated	thisregimen	fda	approved	poly(lactic-co-glycolic	acid)-poly(ethylene	glycol)(plga-peg)	nps	reduce	systemic	side	effects	enhance	cellular	uptake	improve	wtmn	stability	increase	therapeutic	efficacy	treatment	ofplatinum-sensitive	(psoc)	murine	models	thesedual-drug	loaded	(dnps)	significantly	reduced	tumor	burden	versus	treatmentwith	combinations	free	drugs	or	single-drug	(snps)	these	resultssupport	further	investigation	this	np-based	synergistic	drug	regimen	ameans	combat	the	clinic
